INTRODUCTION {#S1}
============

Reduced bone mineral density (BMD) has been increasingly recognized as a complication of hematopoietic cell transplantation (HCT) in children, although the data remain limited to a few retrospective studies^[@R1]--[@R7]^ and one prospective study^[@R8]^. Most of these studies used dual-energy x-ray absorptiometry (DXA) to measure total body BMD (TBMD) Z-score (the number of SDs from the mean)^[@R9]^ and/or lumbar spine BMD (LBMD) Z-score, which are the preferred measures in children^[@R2],\ [@R3],\ [@R5]--[@R7],\ [@R9]^, with average BMD Z-scores ranging from −0.3 to −1.0^[@R2]--[@R5],\ [@R7],\ [@R8]^. This shift in the distribution of BMD Z-scores resulted in a high proportion of children having BMD Z-scores less than −1 (33%) and less than −2 (21%)^[@R4],\ [@R5],\ [@R8]^. Bone quality is also impaired in children after HCT with reductions in both trabecular and cortical dimensions documented by quantitative computed tomography (QCT)^[@R1],\ [@R4]^. Detection of BMD deficits already during childhood is significant because childhood and adolescence are critical periods for establishing adequate bone mass for the rest of a person's life^[@R10],\ [@R11]^. In this context, identification of risk factors in children undergoing HCT takes on heightened importance, but has been limited by small sample size of most pediatric studies.

Post-transplant bone loss results from decreased bone formation (caused by reduced osteoblast activity) and increased bone resorption (due to increased osteoclast activity) within 100 days after pediatric HCT^[@R8],\ [@R12]^. Consequently, LBMD Z-score decreases on average by 0.5 SD within the first 6 months after HCT and, in about a third of the children, remains below the pre-HCT baseline after 1 year^[@R8]^. Potential underlying causes of this post-HCT bone loss are numerous, including poor nutritional status, inadequate calcium and/or vitamin D intake, reduced physical activity, growth hormone deficiency (GHD), hypogonadism, reduced lean body mass (LBM), corticosteroid treatment, exposure to total body irradiation (TBI), cranial radiation (CRT), graft-versus-host disease (GVHD) or its treatment, direct effects of conditioning regimens on bone marrow stromal cells, or cytokine release after HCT^[@R1],\ [@R8],\ [@R13]--[@R16]^. Some of these potential causes persist long after HCT.

The impact of age at HCT is currently unknown. Skeletal weight increases dramatically up to age 25 years with the greatest increase in LBMD and TBMD occurring between the ages of 10 and 16 years^[@R17],\ [@R18]^. Thus, children who were transplanted at a younger age would be expected to have a chance to regain BMD in a rapid period of bone acquisition during puberty and to have better BMD outcome than children transplanted at an older age. This uncertainty about long-term impact of HCT on BMD in the youngest patients complicates a decision about initiating therapeutic interventions when low BMD is diagnosed.

The goal of this study was to examine the association of age at HCT with BMD Z-scores. We hypothesized that younger age at HCT is associated with higher BMD Z-scores at long-term follow-up. A secondary goal was to examine the association between BMD Z-scores and measures of body composition and other potential risk factors.

MATERIALS AND METHODS {#S2}
=====================

Participants {#S3}
------------

All HCT recipients ≤21 years at diagnosis, ≥10 years old at study entry, ≥2 years post-HCT performed to treat hematologic malignancies between 1975 and 2008 at the University of Minnesota or the Fred Hutchinson Cancer Research Center/Seattle Children's Hospital were identified. Of 557 eligible patients, 26 were excluded due to active GVHD or lack of remission; 84 could not be located. Of the remaining 447 patients, contact was attempted with the first 339 randomly selected individuals and consent for participation was obtained from 154 (45%). Of those, 3 were subsequently excluded due to previously undiagnosed diabetes (n=1), severe hypertension (n=1), or multiple medical problems (n=1), leaving the final study population of 151 patients. Allogeneic HCT was performed in 116 (77%) and autologous in 35 (23%) patients; 12 patients had more than one HCT. All patients received myeloablative preparative regimens, 116 (77%) including TBI and 35 (23%) consisting of chemotherapy only, the majority of those busulfan based. Of patients who received TBI, 31 (21%) also received CRT either before or concurrent with TBI.

The control group consisted of eligible healthy siblings who were ≥10 years old at study entry and who had never had a malignancy or HCT. Based on a pre-determined frequency matched enrollment scheme, siblings were recruited to represent the age and sex distribution of HCT recipients. Having a sibling was not a requirement for participation. A siblings control population was chosen to obtain greater similarity to HCT recipients in genetics, lifestyle, and environment/geographical trends.

This study was approved by the Institutional Review Boards at Seattle Children's Hospital and the University of Minnesota Medical Center. Assent was obtained from minors and consent obtained from their parents or guardian(s).

Study procedures {#S4}
----------------

All HCT recipients and controls prospectively underwent a physical examination, including Tanner staging of pubertal development by trained pediatric providers, measurement of height, weight, body mass index (BMI), and a DXA scan (GE Healthcare Lunar Prodigy scanner; Madison, WI, USA) using enCORE software version 9.3 at the University of Minnesota and version 8.1 at Seattle Children's Hospital. DXA measures included Z-scores for total body BMD (TBMD, not excluding head), posterior anterior lumbar spine at L2-L4 (LBMD), femoral neck (FNBMD; only for subjects ≥20 years at study visit), and body composition (percent fat mass, total fat mass, LBM). The two GE Healthcare Lunar Prodigy DXA scanners were cross-calibrated using a custom-built phantom allowing calibration of bone, fat, and lean tissue mass. Data from the two scanners were corrected for differences between them. Sex- and age-specific BMD Z-scores were calculated using enCORE reference data based on healthy, ambulatory subjects from the general population who were free from chronic diseases affecting bone and not taking bone-altering medications.

Laboratory testing included free thyroxine (free T4) by competitive immunoassay and total testosterone by liquid chromatography/tandem mass spectrometry. Chemiluminescent immunoassay was performed to measure follicle stimulating hormone (FSH), luteinizing hormone (LH), and insulin-like growth factor-1 (IGF-1). Hypothyroidism was defined by treatment with thyroid hormone replacement at the time of examination or free T4 \< 0.7 ng/dL (9 pmol/L). Hypergonadotropic hypogonadism was defined by FSH \> 40 IU/L in females or LH \> 10 IU/L and testosterone below normal for Tanner stage in males^[@R19]^. Growth hormone (GH) stimulation test using clonidine and arginine was performed in patients \<18 years at evaluation^[@R20],\ [@R21]^. In patients ≥18 years, growth hormone releasing hormone (GHRH) and arginine or arginine alone (after GHRH ceased being manufactured) were used ^[@R22]^. GHD was defined as a stimulated GH level \<10 μg/L after clonidine/arginine^[@R23]^, \<4.1 μg/L after GHRH-arginine ^[@R22]^, and \<0.4 μg/L after arginine^[@R22]^. GH testing was not performed in sibling controls. Dietary intake of calcium and vitamin D over the past 4 weeks were evaluated using the Youth/Adolescent Questionnaire^[@R24]^. Television/computer screen time was assessed by the Modifiable Activity Questionnaire and used as a measure of leisure activity over the past year^[@R25]^.

Statistical analysis {#S5}
--------------------

Descriptive statistics are shown as frequencies and percents, or as mean ± standard deviation (SD) for unadjusted analyses, or as adjusted average ± standard error (SE) for adjusted analyses. For unadjusted comparisons of patients by age at HCT, *P* values are from one-way ANOVA or Fisher's exact test. Otherwise, all analyses had the form of multivariate linear, logistic, or multinomial regression, depending on the outcome. Analyses involving both HCT recipients and controls used generalized estimating equations (GEE) with robust standard errors to account for sibling relationships between them. Analyses involving only HCT recipients used independent-observations analyses.

Analyses testing the association between BMD Z-score and risk factors in HCT recipients were adjusted for Tanner stage and height Z-score. The following risk factors were considered: age at HCT, gender, BMI percentile, percent fat mass, LBM adjusted for height, IGF-1 SDs, calcium intake, vitamin D intake, screen time, hypothyroidism, hypogonadism, GHD, cumulative dose of steroids, conditioning regimens (chemotherapy, TBI, CRT), history of acute GVHD grades II--IV, and history of chronic GVHD (limited or extensive).

In exploratory analyses, each of the TBMD and LBMD Z-scores was associated with height Z-score, with the association following a straight line with a change in the line's slope at height Z-score = −0.5. Thus in analyses adjusting for height Z-score, height Z-score was entered linearly with a change in slope at height Z-score = −0.5. Height Z-score and BMI percentile were calculated using 2000 CDC growth charts. All analyses were done using the SAS system (v. 9.2; SAS Institute, Cary, NC). All P-values are two-sided and \<0.05 is considered statistically significant.

RESULTS {#S6}
=======

Participant characteristics {#S7}
---------------------------

Participants included 151 HCT recipients and 92 sibling controls aged 10--50.5 years and 10.5--48 years at study visit respectively. Age at most recent HCT was 6 months-25.2 years (84% were \<18 years at HCT), and time since HCT was 2.6--31.5 years. The long-term follow up and wide range of ages at HCT provided an opportunity to examine the impact of age at time of HCT on BMD Z-scores. [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"} show characteristics of the study population.

Bone mineral density {#S8}
--------------------

As shown in [Fig. 1](#F1){ref-type="fig"}, the age-at HCT groups differed in TBMD and FNBMD Z-scores. Patients \<10 years at HCT had BMD Z-scores significantly lower compared to those \>18 years at HCT and controls (by 0.5 SD on average for TBMD and 0.8 SD for FNBMD for both group comparisons). Time since transplant was similar for patients \<10 and \>18 years at HCT ([Table 1](#T1){ref-type="table"}). Patients who were 10--18 years at HCT had intermediate Z-scores between the other two age-at-HCT groups ([Fig. 1](#F1){ref-type="fig"}) and a higher proportion of them had TBMD Z-score ≥ −1 compared to controls ([Table 3](#T3){ref-type="table"}). Although there were no significant differences between age-at-HCT groups in mean LBMD Z-scores ([Fig. 1](#F1){ref-type="fig"}), prevalence of LBMD Z-scores ≤ −1 was significantly higher in patients \<10 at HCT than in controls ([Table 3](#T3){ref-type="table"}).

Compared to patients \>18 at HCT, those \<10 years at HCT were younger at study entry, had lower height Z-score, lower BMI percentile, lower total fat mass adjusted for height, higher prevalence of hypothyroidism, and higher proportion exposed to TBI+CRT ([Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}). All patients (except one in the 10--18 age group) were euthyroid at the study visit.

Risk factors associated with lower BMD in HCT recipients {#S9}
--------------------------------------------------------

[Table 4](#T4){ref-type="table"} shows risk factors that were significantly associated with lower BMD Z-scores, including age at HCT, female sex, lower BMI percentile, lower LBM, lower IGF-1 SDs, GHD, lower calcium intake, lower vitamin D intake, and CRT. The age-at-HCT effect remained significant after adjusting the analysis further for sex and time since HCT (estimated effect of a 1-year increase in age-at-HCT 0.04, SE 0.013, *P*=0.002). The addition of CRT to chemotherapy and TBI lowered TBMD Z-score by an average of 0.5 compared to receiving chemotherapy only or chemotherapy+TBI.

To investigate possible explanations for the higher risk of lower BMD in females, male and female HCT recipients were compared according to body composition, screen time, calcium and vitamin D intake, prevalence of hypothyroidism, hypogonadism, and GHD. Compared to males, females had higher percent fat mass, higher total fat mass adjusted for height, lower LBM adjusted for height, lower calcium intake, and a trend toward a higher prevalence of hypothyroidism ([Table 5](#T5){ref-type="table"}). Although differences in body composition and calcium intake were statistically significant, they were similar to gender differences observed in controls except for LBM, where the differences for female vs. male HCT recipients were greater than in controls (*P*=0.0007). After adjusting for LBM and hypothyroidism, female patients still had lower TBMD Z-score by 0.4 (*P*=0.02) and LBMD Z-score by 0.5 (*P*=0.009) than males.

DISCUSSION {#S10}
==========

This study found that children transplanted at a younger age (\<10 years) have lower TBMD and FNBMD Z-scores at an average of 14 years after HCT compared to patients transplanted at an older age (and to controls). Also, a larger proportion of those transplanted at age \<10 years have LBMD Z-score ≤ −1 compared to controls. This is contrary to our hypothesis and studies in survivors of childhood cancer (who did not have HCT), showing that children \<10 years at diagnosis have higher BMD than children \>10 years at diagnosis^[@R26],\ [@R27]^. This suggests that HCT during childhood interrupts a critical period of bone acquisition during this time period and that an early insult to bone cells or stromal microenvironment has more lasting effects in younger patients. Our study's finding that FNBMD is preferentially affected is consistent with long-term studies in adult HCT recipients^[@R28]--[@R30]^. Some of these differences in vulnerability to HCT effects may be due to different bone architecture at different skeletal sites, i.e., predominantly trabecular bone in the lumbar spine and cortical bone in the femoral neck.

While it is encouraging that mean BMD Z-scores in HCT recipients were \>−2 (lower limit of normal), the difference of 0.5 SD in TBMD Z-score and 0.8 SD at the femoral neck is likely to be clinically significant. Based on logistic regression results in a study by Clark *et al*.^[@R31]^, in a general pediatric population the risk of fracture increases by an estimated 37% for a 0.5 SD decrease in size-adjusted bone mineral content, which is comparable to a Z-score reduction of 0.5. In HCT recipients, fracture incidence is currently unknown because either fractures were not recorded in the published studies or fracture data were based on patient recall. In a study performed 3--16 years after pediatric HCT, 8 out of 55 patients (15%) reported fractures after transplant^[@R1]^. Self-report underestimates the incidence of vertebral fractures, which are common in children after HCT (about 20%)^[@R32]^ yet frequently asymptomatic and therefore unrecognized for a long time in up to 80% of patients^[@R32],\ [@R33]^. This is important since vertebral fractures are indicators of poor bone quality and strength^[@R33]^. Studies in adults have shown that even a small reduction in BMD increases the risk of fractures in patients with impaired bone architecture^[@R33],\ [@R34]^. In addition, patients after HCT may have impaired balance and thus a greater risk of falling as a result of neurotoxic effects of chemotherapy^[@R35]^. All these factors must be considered when estimating fracture risk in this patient population.

There are several potential explanations for this study's age-specific differences in BMD outcome. Even though time since transplant was similar in those who received HCT at age \<10 years and at \>18 years, the first group was also younger at evaluation. However, at the proximal femur, 75--80% of adult peak BMD is achieved by age 12--13 years^[@R11]^ and all patients who had FNBMD measured, including controls, were ≥20 years. Higher prevalence of hypothyroidism in the group \<10 years at HCT is consistent with other studies that found a strong association between young age at HCT and thyroid dysfunction, likely due to higher sensitivity of the thyroid gland to radiation in younger patients^[@R36],\ [@R37]^. It is difficult to determine if hypothyroidism and lower BMD Z-score are causally related in this cohort because all patients (except one) were euthyroid at the study visit. It is more likely that hypothyroidism reflects therapeutic exposure that has also contributed to impaired bone mineralization. In fact, patients \<10 years at HCT differed significantly from other age-at-HCT groups in both diagnosis and exposure to TBI+CRT versus chemotherapy-only or chemotherapy+TBI conditioning.

A secondary goal of this study was to examine the association between BMD Z-scores and measures of body composition and other potential risk factors. This study found that lower BMI percentile, lower LBM, lower IGF-1 SDs, lower calcium and vitamin D intake as well as female sex, GHD, and CRT were associated with lower BMD Z-scores. The latter two factors may reflect strong association between GHD and CRT^[@R38]^. This study does not provide a clear explanation for the gender differences in BMD Z-scores but suggests that lower LBM (after accounting for the expected sex difference) and a higher rate of hypothyroidism may contribute to lower BMD in females. A recent study of childhood cancer survivors who did not undergo HCT also identified female sex as a risk factor for higher prevalence of fractures among aging female survivors^[@R35]^. TBI has been shown to be a risk factor for bone loss^[@R1]^. In the present study, TBI did not show a significant association with BMD Z-scores, although a larger proportion of patients \<10 years at HCT received TBI alone or TBI+CRT compared to patients \>18 years at HCT.

This study has several limitations. Since the population was predominantly white, the findings may not generalize to other racial groups. The cross-sectional design did not allow evaluation of BMD recovery over time. While DXA has several advantages, including low radiation exposure, ease of administration, and availability of body composition data, it does not provide information about bone architecture or strength. Although there was no direct measure of physical activity, screen time has been validated as a surrogate measure^[@R39],\ [@R40]^. Data on fractures were not collected, nor were radiographs of the thoracolumbar spine performed. Undetected compression fractures could have falsely increased LBMD, masking the difference between HCT recipients and controls.

In summary, this study identified young age at transplant as an important risk factor for bone deficits in young adulthood, suggesting that efforts to reduce bone loss should focus on this patient population. Patients should be screened periodically, particularly if other risk factors are present and offered appropriate intervention including optimization of calcium and vitamin D intake, exercise to improve body composition, and, when appropriate, GH supplementation.
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![Total body, lumbar spine, and femoral neck BMD Z-scores adjusted for height Z-scores according to age at HCT\
Data are shown as adjusted average ± SE. Femoral neck BMD Z-scores were obtained only in HCT recipients and controls ≥20 years at study visit. Patients \<10 years at HCT show the greatest BMD deficits.](nihms518350f1){#F1}

###### 

Characteristics of study participants.

  Characteristic                                    Controls   Age (yr) at HCT                                Pairwise *P* values                                                                                                         
  ------------------------------------------------- ---------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- -------------- -------------- --------------
  n                                                 92         76                                             51                                             24                                             \-             \-             \-
  Male                                              49 (53)    47 (62)                                        26 (51)                                        14 (58)                                        0.29           0.84           0.55
  Race                                                                                                                                                                                                                                    
   Non-black                                        90 (98)    71 (93)                                        51 (100)                                       23 (96)                                        0.082          1.00           0.32
   Black                                            2 (2)      5 (7)                                          0 (0)                                          1 (4)                                                                        
  Age at study (yr)                                 22.3±8.0   20.5±6.4                                       26.6±7.6[\*\*\*](#TFN7){ref-type="table-fn"}   34.1±8.4[\*\*\*](#TFN7){ref-type="table-fn"}   **\<0.0001**   **\<0.0001**   **0.0002**
  Age at HCT (yr)                                   \-         5.5±2.7                                        14.3±2.2                                       20.8±1.8                                       **\<0.0001**   **\<0.0001**   **\<0.0001**
  Time since HCT (yr)                               \-         15.0±6.2                                       12.2±7.4                                       13.3±7.7                                       **0.024**      0.27           0.54
  Tanner stage[a](#TFN2){ref-type="table-fn"}                  **0.024**                                      0.38                                           0.73                                           **0.003**      0.055          1.00
   I                                                2 (2)      6 (8)                                          0 (0)                                          0 (0)                                                                        
   II--III                                          5 (6)      11 (15)                                        1 (2)                                          0 (0)                                                                        
   IV--V                                            79 (92)    55 (77)                                        47 (98)                                        21 (100)                                                                     
   Median                                           5          5                                              5                                              5                                                                            
   Missing, n                                       6          4                                              3                                              3                                                                            
  Height Z-score                                    0.4±0.9    −1.2±1.2[\*\*\*](#TFN7){ref-type="table-fn"}   −0.3±1.1[\*\*\*](#TFN7){ref-type="table-fn"}   0.1±1.2                                        **\<0.0001**   **\<0.0001**   0.15
  BMI percentile                                    62±26      47±34[\*\*\*](#TFN7){ref-type="table-fn"}      58±33                                          68±28                                          0.06           **0.003**      0.17
  Screen time (≥2 hr)                               52 (66)    56 (79)                                        31 (70)                                        12 (67)                                        0.22           0.22           0.84
  IGF-1 SDs                                         −0.6±0.9   −1.2±1.1[\*](#TFN5){ref-type="table-fn"}       −1.3±0.9[\*\*\*](#TFN7){ref-type="table-fn"}   −1.4±1.1[\*\*\*](#TFN7){ref-type="table-fn"}   0.51           0.40           0.77
  GH deficiency                                     \-         11 (19)                                        5 (11)                                         1 (4)                                          0.26           0.12           0.36
  Hypothyroidism                                    1 (1)      36 (47)[\*\*\*](#TFN7){ref-type="table-fn"}    11 (22)[\*\*](#TFN6){ref-type="table-fn"}      4 (17)[\*\*](#TFN6){ref-type="table-fn"}       **0.0042**     **0.013**      0.72
  Hypogonadism                                      1 (1)      8 (11)[\*](#TFN5){ref-type="table-fn"}         11 (22)[\*\*](#TFN6){ref-type="table-fn"}      4 (17)[\*](#TFN5){ref-type="table-fn"}         0.093          0.36           0.67
  Calcium intake[b](#TFN3){ref-type="table-fn"}     1090±498   1022±546                                       964±422                                        954±313                                        0.68           0.52           0.83
  Vitamin D intake[c](#TFN4){ref-type="table-fn"}   270±179    266±199                                        227±161                                        277±159                                        0.24           0.91           0.28

Data are presented as average ± SD, adjusted average ± SE for adjusted characteristics, or n (%).

*P* value refers to the difference, between groups, in the distribution of Tanner stage among the available categories.

expressed in mg/day,

expressed in IU/day,

*P* \<0.05,

*P* \<0.01,

*P* \<0.001 indicate significant difference between a given age-at-HCT group and controls. The *P* values are provided for the purposes of exploratory comparisons.

###### 

Diagnosis and treatment characteristics in HCT recipients.

  Characteristic                                                          Age (yr) at HCT   Pairwise *P* values                                                                                                
  ----------------------------------------------------------------------- ----------------- --------------------- ----------- ------------------------------------- ------------------------------------------ --------------------------------------
  n                                                                       76                51                    24          \-                                    \-                                         \-
  Malignancy                                                                                                                                                                                                   
   Lymphoid                                                               36 (47)           17 (33)               3 (13)      0.14                                  **0.0039**                                 0.09
   Myeloid                                                                38 (50)           28 (55)               12 (50)     0.72                                  1.00                                       0.81
  Type of transplant                                                                                                          0.65[a](#TFN9){ref-type="table-fn"}   0.18[a](#TFN9){ref-type="table-fn"}        0.083[a](#TFN9){ref-type="table-fn"}
   Autologous                                                             17 (22)           9 (18)                9 (38)                                                                                       
   Allogeneic                                                             59 (78)           42 (82)               15 (62)                                                                                      
  Conditioning regimen                                                                                                        0.09[a](#TFN9){ref-type="table-fn"}   **0.014**[a](#TFN9){ref-type="table-fn"}   0.46[a](#TFN9){ref-type="table-fn"}
   Chemotherapy                                                           12 (16)           15 (29)               8 (33)                                                                                       
   Chemo+TBI                                                              42 (55)           28 (55)               15 (63)                                                                                      
   Chemo+TBI+CRT                                                          22 (29)           8 (16)                1 (4)                                                                                        
  TBI                                                                     64 (84)           36 (71)               16 (67)     0.08                                  0.08                                       0.79
  TBI+CRT                                                                 22 (29)           8 (16)                1 (4)       0.09                                  **0.012**                                  0.26
  Acute GVHD                                                              36 (47)           22 (43)               11 (46)     0.72                                  1.00                                       1.00
  Chronic GVHD                                                            20 (26)           16 (31)               7 (29)      0.55                                  0.80                                       1.00
  Cumulative dose of steroids (mg/m^2^)[b](#TFN10){ref-type="table-fn"}   3587±3971         5166±6808             5667±7035   0.22                                  0.34                                       0.83

Data are presented as average ± SD, or n (%).

*P* value refers to the difference, between groups, in the distribution of the outcome among the available categories,

expressed as total dose in milligrams of prednisone equivalent received during and after HCT. Diagnoses included acute myeloid leukemia (AML, n=54), acute lymphoblastic leukemia (ALL, n=47), chronic myeloid leukemia (CML, n=15), myelodysplastic syndrome (MDS, n=13), Hodgkin's disease (HD, n=12), and non-Hodgkin lymphoma (NHL, n=10). CRT, cranial radiation, GVHD, graft versus host disease, Acute GVHD: any grade II--IV GVHD. Chronic GVHD: any chronic GVHD, TBI, total body irradiation. Lymphoid malignancy: ALL and NHL, myeloid malignancy: AML+CML+MDS.

###### 

DXA measures.

  Characteristic                                   Controls    Age (yr) at HCT                              Pairwise *P* values                                                                                                    
  ------------------------------------------------ ----------- -------------------------------------------- ----------------------------------------------- ---------------------------------------------- ------------ ---------- ------
  n                                                92          76                                           51                                              24                                             \-           \-         \-
  Percent fat mass                                 26.4±10.7   29.2±10.1[\*](#TFN13){ref-type="table-fn"}   35.3±9.3[\*\*\*](#TFN15){ref-type="table-fn"}   33.4±11.0[\*\*](#TFN14){ref-type="table-fn"}   **0.0013**   0.16       0.43
  Total fat mass[a](#TFN12){ref-type="table-fn"}   17.8±1.1    17.5±1.3                                     24.8±2.0[\*\*](#TFN14){ref-type="table-fn"}     23.4±2.2[\*](#TFN13){ref-type="table-fn"}      **0.0007**   **0.03**   0.65
  Lean body mass[a](#TFN12){ref-type="table-fn"}   44.9±0.7    43.8±0.7                                     42.3±1.1                                        43.9±1.4                                       0.25         0.91       0.37
  TBMD Z-score ≤ −1                                6 (7)       11 (15)                                      9 (18)[\*](#TFN13){ref-type="table-fn"}         2 (8)                                          0.63         0.43       0.29
  LBMD Z-score ≤ −1                                13 (14)     21 (28)[\*](#TFN13){ref-type="table-fn"}     8 (16)                                          4 (17)                                         0.13         0.26       0.97

Data are presented as average ± SD, adjusted average ± SE for adjusted characteristics, or n (%).

expressed in kg, adjusted for height (cm),

*P* \<0.05,

*P* \<0.01,

*P* \<0.001 indicate significant difference between a given age-at-HCT group and controls. The *P* values are provided for the purposes of exploratory comparisons.

###### 

Factors significantly associated with BMD in HCT recipients.

  Total BMD Z-score                                                          
  ------------------------------------ --------------------- --------------- ------------
  Age at HCT                           1 year increase       0.03 (0.016)    **0.0354**
  Gender                               Male vs. Female       0.52 (0.167)    **0.0024**
  BMI Percentile                       1 % increase          0.01 (0.003)    **0.0391**
  Lean body mass adjusted for height   1 kg increase         0.04 (0.012)    **0.0004**
  IGF-1 SDs                            1 unit increase       0.20 (0.100)    **0.0472**
  GHD                                  Yes vs. No            −0.77 (0.262)   **0.0041**
  Calcium intake (mg/day)              100 mg/day increase   0.06 (0.018)    **0.0016**
  Vitamin D intake (IU/day)            100 IU/day increase   0.16 (0.047)    **0.0007**
  CRT                                  Yes vs. No            −0.50 (0.205)   **0.0160**

  Lumbar BMD Z-score                                                        
  ------------------------------------ --------------------- -------------- ------------
  Gender                               Male vs. Female       0.48 (0.191)   **0.0134**
  Lean body mass adjusted for height   1 kg increase         0.03 (0.014)   **0.0430**
  Vitamin D intake (IU/day)            100 IU/day increase   0.13 (0.054)   **0.0189**

Each of these risk factors was considered separately in an analysis adjusting for Tanner stage, height Z-score, and height Z-score spline at −0.5. Preliminary analyses using a loess smoother showed straight-line relationships between each BMD measure and height Z- score but with a change of the straight line's slope at height Z-score = −0.5. Thus to adjust for height Z-score, the slope of each outcome on height Z-score was allowed to change at height Z-score = −0.5. GHD, growth hormone deficiency. This table includes only risk factors with *P* \< 0.05, the methods section lists all risk factors considered.

###### 

Characteristics of HCT recipients by gender

  Characteristic                            Male         Female       *P* value
  ----------------------------------------- ------------ ------------ --------------
  n                                         87           64           
  Percent fat mass                          27.5 ± 9.1   38.1 ± 8.6   **\<0.0001**
  Total fat mass (kg) adjusted for height   17.0 ± 1.2   25.2 ± 1.5   **\<0.0001**
  Lean body mass (kg) adjusted for height   42.8 ± 0.7   37.9 ± 0.9   **\<0.0001**
  Calcium intake (mg/day)                   1062 ± 507   881 ± 403    **0.0219**
  Vitamin D intake (IU/day)                 265 ± 169    238 ± 197    0.40
  Hypothyroidism                            24 (28)      27 (42)      0.0814
  Hypogonadism                              10 (11)      13 (20)      0.17

Data are presented as average ± SD, adjusted average ± SE for adjusted characteristics, or n (%).
